Science Explorer Back to mapMap

Most cited papers from Alleanza Contro il Cancro

What are the most cited papers from Alleanza Contro il Cancro?

The most cited paper from Alleanza Contro il Cancro is "Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer" (Jan B. Vermorken, Ricard Mesı́a, Fernando Rivera et al., 2008), with 3,762 citations. Next come "Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia" (2,607) and "Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis" (1,785).

Showing 50 of 60 papers. Every paper with more than 470 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Jan B. Vermorken, Ricard Mesı́a, Fernando Rivera et al. · New England Journal of Medicine Open access 10 Sep 2008 3,762
2 Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia Rajendra N. Damle, Tarun Wasil, Franco Fais et al. · Blood 15 Sep 1999 2,607
3 Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis Alessandro Moretta, Cristina Bottino, Massimo Vitale et al. · Annual Review of Immunology Review Apr 2001 1,785
4 HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures Michael Felix Fenech, Wushou P. Chang, Micheline Kirsch‐Volders et al. · Mutation Research/Genetic Toxicology and Environmental Mutagenesis 28 Dec 2002 1,395
5 Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium Graziella Pellegrini, Carlo Enrico Traverso, Adriano Tito Franzi et al. · The Lancet Apr 1997 1,387
6 Repair of Large Bone Defects with the Use of Autologous Bone Marrow Stromal Cells Rodolfo Quarto, Maddalena Mastrogiacomo, Ranieri Cancedda et al. · New England Journal of Medicine Feb 2001 1,379
7 Capecitabine as Adjuvant Treatment for Stage III Colon Cancer Chris J. Twelves et al. · New England Journal of Medicine Open access 29 Jun 2005 1,256
8 Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial Arnaud D. Roth, Sabine Tejpar, Mauro Delorenzi et al. · Journal of Clinical Oncology 15 Dec 2009 1,168
9 Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2 Grazia Maria Spaggiari, Andrea Capobianco, Heba Abdelrazik et al. · Blood 19 Oct 2007 1,157
10 Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells Guido Ferlazzo, Ming Li Tsang, Lorenzo Moretta et al. · The Journal of Experimental Medicine Open access 4 Feb 2002 986
11 Cancer incidence and mortality in Europe Fabio Levi, Patrick Maisonneuve, Rosangela Filiberti et al. · Sozial- und Präventivmedizin Mar 1989 971
12 Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 Alan Stuart Coates, Aparna P. Keshaviah, Beat J. K. Thurlimann et al. · Journal of Clinical Oncology 2 Jan 2007 911
13 Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. Franco Fais, Fabio Ghiotto, Shiori Hashimoto et al. · Journal of Clinical Investigation Open access 15 Oct 1998 886
14 AU Binding Proteins Recruit the Exosome to Degrade ARE-Containing mRNAs Ching‐Yi Chen, Roberto Gherzi, Shao‐En Ong et al. · Cell Open access Nov 2001 880
15 Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule Cristina Bottino, Roberta Castriconi, Daniela Pende et al. · The Journal of Experimental Medicine Open access 11 Aug 2003 868
16 Early Interim 2-[ 18 F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study Andrea Gallamini, Martin Hutchings, Luigi Rigacci et al. · Journal of Clinical Oncology 23 Jul 2007 846
17 Consensus guidelines for the detection of immunogenic cell death Oliver Kepp et al. · OncoImmunology Open access 2 Sep 2014 842
18 Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen Mitch Dowsett, Jack M. Cuzick, J. N. Ingle et al. · Journal of Clinical Oncology Review 30 Nov 2009 818
19 Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages Mihai Gheorghe Netea, Claudia A. Nold‐Petry, Marcel F. Nold et al. · Blood Open access 22 Dec 2008 795
20 A novel secretory pathway for interleukin‐1 beta, a protein lacking a signal sequence. Anna Rubartelli, Federico Cozzolino, M. Talio et al. · The EMBO Journal Open access May 1990 787
21 Autologous Transplantation and Maintenance Therapy in Multiple Myeloma Antonio Palumbo et al. · New England Journal of Medicine Open access 3 Sep 2014 786
22 Identification and Molecular Characterization of Nkp30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells Daniela Pende, Silvia Parolini, Anna Maria Pessino et al. · The Journal of Experimental Medicine Open access 15 Nov 1999 785
23 Adjuvant Mitotane Treatment for Adrenocortical Carcinoma Massimo Terzolo et al. · New England Journal of Medicine Open access 6 Jun 2007 766
24 Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells Andrea Banfi, Anita Muraglia, Béatrice Dozin et al. · Experimental Hematology Open access Jun 2000 731
25 The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs Michèle Trabucchi, Paola Briata, MaríaFlor García-Mayoral et al. · Nature Open access 20 May 2009 657
26 Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. Chao‐Kai Chou, Thomas J. Dull, David Russell et al. · Journal of Biological Chemistry Open access Feb 1987 649
27 Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia. Dan Y. Wu, Luis A. Ugozzoli, B K Pal et al. · Proceedings of the National Academy of Sciences Open access Apr 1989 629
28 Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Loredana Ruggeri, Antonella Mancusi, Marusca Capanni et al. · Blood Open access 19 Mar 2007 611
29 The HUman MicroNucleus Project—An international collaborative study on the use of the micronucleus technique for measuring DNA damage in humans Michael Felix Fenech, Nina Holland, Wushou Peter Chang et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis Jul 1999 607
30 Stem Cells Associated with Macroporous Bioceramics for Long Bone Repair: 6- to 7-Year Outcome of a Pilot Clinical Study Maurilio Marcacci, Elizaveta Kon, Vladimir Moukhachev et al. · Tissue Engineering 20 Mar 2007 588
31 SOX2 Silencing in Glioblastoma Tumor-Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity Rosaria M. R. Gangemi, Fabrizio Griffero, Daniela Marubbi et al. · Stem Cells 24 Oct 2008 583
32 Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs Guido Ferlazzo, Maggi Pack, Dolca A. Thomas et al. · Proceedings of the National Academy of Sciences Open access 9 Nov 2004 578
33 The Abundant NK Cells in Human Secondary Lymphoid Tissues Require Activation to Express Killer Cell Ig-Like Receptors and Become Cytolytic Guido Ferlazzo, Dolca A. Thomas, Shao‐Lee Lin et al. · The Journal of Immunology Open access Feb 2004 578
34 Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains Nicolai R. Wagtmann, Roberto Biassoni, Claudia Cantoni et al. · Immunity Open access May 1995 577
35 Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial Thomas Suter, Marion Jennifer Procter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology Open access 24 Jul 2007 568
36 Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors Sebastian Giebel · Blood 3 Apr 2003 551
37 A case‐control study of gastric cancer and diet in Italy Eva Buiatti, Domenico Palli, Adriano Decarli et al. · International Journal of Cancer 15 Oct 1989 548
38 A tissue engineering approach to bone repair in large animal models and in clinical practice Ranieri Cancedda, Paolo Giannoni, Maddalena Mastrogiacomo · Biomaterials 18 Jul 2007 543
39 Identification of a Wnt/Dvl/β-Catenin → Pitx2 Pathway Mediating Cell-Type-Specific Proliferation during Development Chrissa Kioussi, Paola Briata, Sung Hee Baek et al. · Cell Open access Nov 2002 542
40 The Receptor with High Affinity for Immunoglobulin E H. Peter Metzger, Gisèle Alcaraz, Robert J. Hohman et al. · Annual Review of Immunology Apr 1986 541
41 Two Pathways for Base Excision Repair in Mammalian Cells Guido Fròsina, Paola Fortini, Ottavio Rossi et al. · Journal of Biological Chemistry Open access Apr 1996 536
42 CRTAP Is Required for Prolyl 3- Hydroxylation and Mutations Cause Recessive Osteogenesis Imperfecta Roy Morello, Terry Bertin, Yuqing Chen et al. · Cell Open access Oct 2006 534
43 First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin Jim Cassidy, Chris J. Twelves, Eric Van Cutsem et al. · Annals of Oncology Open access Apr 2002 529
44 Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. Luigi Solbiati, Tiziana Ierace, Shraga Nahum Goldberg et al. · Radiology 1997 526
45 Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial B-J Kullberg, JD Sobel, Markus Ruhnke et al. · The Lancet Oct 2005 525
46 Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer Timothy R. Rebbeck et al. · JAMA Open access258 authors 7 Apr 2015 517
47 Role of scaffold internal structure on in vivo bone formation in macroporous calcium phosphate bioceramics Maddalena Mastrogiacomo, Silvia Scaglione, Roberta Martinetti et al. · Biomaterials 21 Feb 2006 513
48 Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Daniela Pende, Paola Rivera, Stefania Marcenaro et al. · PubMed Nov 2002 505
49 Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial Alessandro Gronchi et al. · The Lancet Oncology 9 May 2017 498
50 Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Stefano Bonassi, Lars Hagmar, Ulf Strömberg et al. · PubMed 15 Mar 2000 495

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.